



CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium

New Data to be Presented in Many Clinical Applications

MONMOUTH JUNCTION, N.J., March 14, 2016 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, will host its 3rd International CytoSorb® Users Meeting today in Brussels, Belgium. In addition, CytoSorbents will host a research symposium and exhibit at the 36th International Symposium on Intensive Care and Emergency Medicine ([ISICEM 2016](#)), March 15-18, 2016, also in Brussels. ISICEM is among the largest annual conferences for intensive care and emergency medicine, attracting more than 6,200 participants from countries worldwide.

[The Third International CytoSorb® Users Meeting](#)

**Monday, March 14, 2016, 12:00 – 6:30 PM CET, Hitchcock Auditorium
Hotel Marivaux - Boulevard Adolphe Max 98, 1000 Brussels, Belgium**

In advance of ISICEM, members of the CytoSorb® community from around the world will gather at Hotel Marivaux to learn about and discuss some of the most recent advances and knowledge in CytoSorb® treatment for critical illnesses. The agenda is led by presentations from 12 distinguished international speakers focused on CytoSorb's mechanism of action, timing of intervention, and treatment experiences in sepsis, cardiac surgery, liver failure, burn injury, severe acute pancreatitis, trauma, and others. More than 100 people from 22 countries have registered to attend. A full program of the Users Meeting is available [here](#).

In addition, a panel session chaired by Dr. Zsolt Molnár (Szeged, Hungary) with panelists Dr. John Kellum (Pittsburgh, USA), Dr. Albert Grootendorst (Rotterdam, Netherlands), and Dr. Antje-Christin Deppe (Cologne, Germany) will foster discussion amongst attendees and conclude the session.

[CytoSorbents Research Symposium at ISICEM](#)

**Thursday, March 17, 2016, 12:30 to 1:30 PM CET, Copper Hall
Square - Brussels Meeting Center – rue Mont des Arts, 1000 Brussels, Belgium**

CytoSorbents will also sponsor a lunch symposium entitled, “REGAIN CONTROL in SIRS and Sepsis: New insights into the CytoSorb® Therapy” chaired by Dr. John Kellum (Pittsburgh, USA) and Dr. Antonio Pesenti (Milan, Italy)

- The CytoSorb® Therapy: Backgrounds, properties, safety
Detlef Kindgen-Milles, Düsseldorf, Germany
- Clinical progress in the treatment of septic shock patients
Zsolt Molnár, Szeged, Hungary



- Therapeutic options in rhabdomyolysis and liver failure
Axel Nierhaus, Hamburg, Germany

More information about the symposium is available [here](#).

CytoSorbents ISICEM Exhibition Booth

March 15-18, 2016: Silver Foyer, Level 0, At ISICEM

ISICEM attendees can visit CytoSorbents to learn how the CytoSorb® extracorporeal cytokine adsorber may help them regain control of their patients suffering from a dangerous maladaptive systemic inflammatory response syndrome (SIRS) in critical illnesses and cardiac surgery, with the goal of preventing or treating deadly multiple organ failure.

The events will be covered on [Facebook](#) and [Twitter](#)

AT A GLANCE: CYTOSORBENTS at ISICEM

Third International CytoSorb® Users Meeting

March 14, 2016, 12:00 - 6:30PM CET

Hitchcock Auditorium

Hotel Marivaux, Brussels

Scientific Lunch Symposium

March 17, 2016 12:30 PM CET

REGAIN CONTROL in SIRS and Sepsis: New insights into the CytoSorb® Therapy

Copper Room – Square-Brussels Meeting Center

CytoSorbents Conference Exhibition

March 15-18, 2016

Square-Brussels Meeting Center, Silver Foyer, Level 0

About ISICEM

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine. This annual conference was started in 1980 and has become established as one of the largest in its field, now attracting more than 6,000 participants from countries worldwide. The objectives of this four-day symposium are to provide participants with an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses, and other health professionals with an interest in critical care or emergency medicine.



About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 10,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's websites: <http://www.cytosorbents.com> and <http://www.cytosorb.com>

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Cytosorbents Contact:

Amy Vogel



CytoSorbents
Working to Save Lives Through Blood Purification

Investor Relations
(732) 329-8885 ext. *825

Investor Contact:

Lee Roth

The Ruth Group

646-536-7012

lroth@theruthgroup.com